Camp4 Therapeutics Corporation (CAMP)
| Market Cap | 224.29M |
| Revenue (ttm) | 3.50M |
| Net Income (ttm) | -80.40M |
| Shares Out | 51.92M |
| EPS (ttm) | -2.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 47,029 |
| Open | 4.340 |
| Previous Close | 4.440 |
| Day's Range | 4.270 - 4.570 |
| 52-Week Range | 1.305 - 7.750 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 8.60 (+99.07%) |
| Earnings Date | May 7, 2026 |
About CAMP
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015... [Read more]
Financial Performance
In 2025, Camp4 Therapeutics's revenue was $3.50 million, an increase of 436.50% compared to the previous year's $652,000. Losses were -$80.40 million, 55.2% more than in 2024.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CAMP stock is "Buy." The 12-month stock price target is $8.6, which is an increase of 99.07% from the latest price.
News
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
Using epigenomic mapping and regulatory RNA (regRNA) Capture-seq, CAMP4 has assembled what it believes to be the largest catalog of regRNAs ever compiled, uncovering thousands of previously undiscover...
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regul...
Camp4 Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
A proprietary ASO platform is advancing toward clinical trials for SYNGAP1-related disorder, aiming to be first-in-class for this rare epilepsy. Preclinical data show dose-dependent restoration of protein and function, with a pediatric-focused phase I/II trial planned for later this year.
CAMP4 Appoints Michael MacLean to its Board of Directors
CAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regul...
Camp4 Therapeutics Transcript: Stifel 2026 Virtual CNS Forum
The discussion highlighted a CNS-focused platform using oligonucleotides to upregulate gene expression, with the lead program CMP-002 targeting SYNGAP1-related disorders. The phase I/II trial will begin in severe pediatric patients this year, focusing on seizure reduction and other meaningful endpoints, with strong financial runway into 2028.
Camp4 Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The platform uses ASOs to upregulate gene expression by targeting regulatory RNAs, with a focus on haploinsufficient CNS diseases like SYNGAP1. Clinical development is informed by robust preclinical data, natural history studies, and regulatory support, while partnerships like GSK expand reach to other indications.
CAMP4 to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regul...
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026 Entered strategic collaboration with GSK to advance RNA-...
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regula...
Camp4 Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
CMP-002 is advancing as a first-in-class disease-modifying therapy for SYNGAP1 disorders, with robust preclinical data and a global phase I-II trial planned for later this year. The proprietary RAP platform underpins a growing pipeline, supported by strategic partnerships and strong financials through 2027.
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regul...
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or the “Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regula...
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
Collaboration to leverage CAMP4's RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases
Camp4 Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
The company is advancing a platform targeting regulatory RNAs to upregulate gene expression, with a lead program in SYNGAP1-related disorders showing strong preclinical results and clinical entry expected next year. Financially, it is well-funded into 2027 and aims to expand its CNS pipeline.
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
Strengthened balance sheet with private placement of up to $100 million to advance CMP-002, a first-in-class treatment for SYNGAP1-related disorders Initiated Good Laboratory Practice (GLP) toxicolog...
Camp4 Therapeutics Transcript: Chardan's 9th Annual Genetic Medicines Conference
Panelists highlighted advances in non-coding RNA research, with platforms enabling precise target identification and therapeutic development for diseases like CNS disorders and cardiac fibrosis. Strategic focus, strong partnerships, and rigorous validation are driving progress, despite challenges in target validation and drug design.
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regul...
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
Oversubscribed Financing led by Coastlands Capital with participation from new and existing investors Financing to provide $50 million in upfront proceeds with the potential for up to an additional $5...
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targetin...
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting...
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic...
CAMP4 Appoints Multiple Industry Veterans to its Board of Directors
With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D.